M&A: NOVAVAX INC

Form Type: 8-K

Filing Date: 2024-12-30

Corporate Action: Acquisition

Type: New

Accession Number: 000110465924132569

Comments: On December 30, 2024, Novavax CZ a.s., a wholly owned subsidiary of Novavax Inc., completed the sale of its biologics manufacturing campus in Bohumil, Jevany, Czech Republic, to Novo Nordisk Production Czech s.r.o. The acquisition involved the transfer of the facility, certain movable assets, contracts related to the operation, and some employees associated with the manufacturing facility. The total purchase price amounted to $200 million, with a cash payment of $180 million made on the closing date. An initial payment of $10 million was made prior to closing in September 2024, and an additional $10 million was placed in escrow, to be released 12 months post-closing, subject to adjustments for potential claims. Additionally, Novavax was reimbursed approximately $2.6 million for operational costs related to the transferred assets leading up to the sale.

Document Link: View Document